The main point of this post is that filtration treatment at the beginning of drug treatment can improve the efficacy of current treatment and may well improve the efficacy of future drugs and/or make other adjunct drug therapies less desirable. And, of course, the nice thing about this adjunct filtration therapy is that it does not bring any toxicity/side-effect baggage with it. In short, the current ranking of promising HCV drugs treatments may well do some shifting in the next year
Show me the data from a randomzied control trial and I might believe that this idea has some merit. Until then, I’ll probably continue to consider AEMD one of the myriad virtual biotech companies who compete with one another for a share of the dumb money. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
AI
